Related Experiment Videos

Questions and facts regarding denosumab discontinuation among postmenopausal women

Polyzois Makras¹, Athanasios D Anastasilakis²

¹Department of Medical Research; Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.

Expert Opinion on Drug Safety

|December 29, 2020

Abstract

No abstract available in PubMed .

Keywords:

Alendronate denosumab discontinuation osteoporosis zoledronate

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Vitamin D levels and skeletal quality of life in adult Langerhans cell histiocytosis.

Endocrine connections·2026

Real-world data for effectiveness and safety of palopegteriparatide in patients with chronic hypoparathyroidism: the PaTH REAL study.

European journal of endocrinology·2026

Effectiveness of anti-osteoporotic medications in the management of glucocorticoid-induced osteoporosis: a systematic review and network meta-analysis on behalf of the ECTS clinical action group.

European journal of endocrinology·2026

Challenges in Sequential Antiresorptive Therapy After Long-Term Denosumab Discontinuation: A Case Report and Narrative Review of the Literature.

Journal of clinical medicine·2026

Alendronate for 6 or 12 months following denosumab discontinuation in women with postmenopausal osteoporosis: A prospective observational study.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Exploring the relationship between microplastic exposure and bone health.

Endocrine connections·2026

See all related articles